30-MAY-2023 6:10

MMYEL ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S1803-MM, Maintenance, Len vs Len/Dara 1 T 0 Screening 1100 1141 291 154 73 0 0 08/13/2019 316 111
            1141 291 154 73 0 0      
 
    2 Y 1 Lenalidomide   520 129 63 29 4 1 08/13/2019    
        2 Lenalidomide + Daratumumab   512 132 66 28 2 0      
            1032 261 129 57 6 1      
 
    3 Y 3 Stop vs Continue Treatment   93 78 57 24 4 0 08/13/2019    
            93 78 57 24 4 0      
 
  S2005-WM, Prev. Untreated, I/R +/- Venetoclax 1 T 2 I+R+Venetoclax 62 1 0 0 0 0 0 01/05/2022 83 28
            1 0 0 0 0 0      
 
Yes EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) 0 E Total Registrations   24 12 6 3 0 0 05/27/2021 181 72
            24 12 6 3 0 0      
 
    1 E Total Registrations   18 11 6 3 0 0 05/27/2021    
            18 11 6 3 0 0      
 
    2 E Total Registrations   8 6 1 1 1 0 05/27/2021    
            8 6 1 1 1 0      
 
No A061402-Solitary Plasmacytoma, adj sys+Zol vs Zol 0 E Total Registrations   1 0 0 0 0 0 01/27/2017    
            1 0 0 0 0 0      
 
  EAA173-MYEL, SMM, Rd +/- Daratumumab 0 E Total Registrations   49 12 7 5 2 2 01/08/2020 237 97
            49 12 7 5 2 2      
 
    1 E Total Registrations   22 3 1 1 0 0 01/08/2020    
            22 3 1 1 0 0      
 

30-MAY-2023 6:10

MMYEL Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 1 Randomization 30-May-23    
A061402 Solitary Plasmacytoma, adj sys+Zol vs Zol 1 Registration 23-Dec-15